Vireo Growth Inc. has announced the completion of its acquisition of FLUENT Corp., a significant move that positions the company for growth in the competitive pharmaceutical preparations industry. This acquisition, finalized on November 9, 2026, follows a court-approved statutory plan of arrangement, marking a strategic expansion for Vireo.

Vireo Growth Inc., which trades under the ticker VREOF on the OTC exchange, is classified under the SIC code 2834, focusing on pharmaceutical preparations. The company has been active in recent months, with a series of filings indicating its ongoing strategic initiatives, including the acquisition of FLUENT Corp. The most recent filing, dated November 16, 2026, highlights the completion of this acquisition.

According to the filing, the acquisition was executed through a statutory plan of arrangement, which was approved by FLUENT shareholders at a meeting held on July 28, 2026. The Ontario Superior Court of Justice granted the final order approving the plan on August 4, 2026. As part of the transaction, FLUENT's shares were converted into Vireo shares at an exchange ratio adjusted to reflect a previous share consolidation.

In total, Vireo issued 6,148,780 shares as consideration for the acquisition. This strategic move not only enhances Vireo's product offerings but also positions it to leverage FLUENT's existing market presence. FLUENT has now become a wholly owned subsidiary of Vireo, with its shares delisted from the Canadian Securities Exchange.

The completion of this acquisition is expected to impact various stakeholders, including shareholders of both companies and competitors in the pharmaceutical preparations sector. By integrating FLUENT's operations, Vireo aims to strengthen its market position and expand its product portfolio.

The filing does not specify what steps Vireo will take next following the acquisition, but the company has indicated its commitment to enhancing shareholder value through strategic growth initiatives.